Premium
Potential role of LMP2 as an anti‐oncogenic factor in human uterine leiomyosarcoma: Morphological significance of calponin h1
Author(s) -
Hayashi Takuma,
Horiuchi Akiko,
Sano Kenji,
Hiraoka Nobuyoshi,
Kasai Mari,
Ichimura Tomoyuki,
Sudo Tamotsu,
Nishimura Ryuichiro,
Ishiko Osamu,
Shiozawa Tanri,
Kanai Yae,
Yaegashi Nobuo,
Aburatani Hiroyuki,
Konishi Ikuo
Publication year - 2012
Publication title -
febs letters
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.593
H-Index - 257
eISSN - 1873-3468
pISSN - 0014-5793
DOI - 10.1016/j.febslet.2012.05.029
Subject(s) - calponin , myometrium , suppressor , leiomyosarcoma , carcinogenesis , cancer research , neoplasm , biology , medicine , endocrinology , microbiology and biotechnology , smooth muscle , uterus , pathology , cancer , genetics
Uterine leiomyosarcoma (LMS) is a highly metastatic smooth muscle neoplasm for which calponin h1 is suspected to have a biological role as a tumor‐suppressor. We earlier reported that LMP2‐null mice spontaneously develop uterine LMS through malignant transformation of the myometrium, thus implicating this protein as an anti‐tumorigenic candidate as well. In the present study, we show that LMP2 may negatively regulate LMS independently of its role in the proteasome. Moreover, several lines of evidence indicate that although calponin h1 does not directly influence tumorigenesis, it clearly affects LMP2‐induced cellular morphological changes. Modulation of LMP2 may lead to new therapeutic approaches in human uterine LMS.